4//SEC Filing
Thompson Peter A. 4
Accession 0000947871-25-000635
CIK 0001626971other
Filed
Jun 30, 8:00 PM ET
Accepted
Jul 1, 9:17 PM ET
Size
11.0 KB
Accession
0000947871-25-000635
Insider Transaction Report
Form 4
Thompson Peter A
Director10% Owner
Transactions
- Exercise of In-Money
Common Warrants (right to buy)
2025-06-27−1,397,684→ 0 total(indirect: See Footnotes)Exercise: $3.50From: 2025-04-29Exp: 2025-06-30→ Common Stock (1,397,684 underlying) - Exercise of In-Money
Common Stock
2025-06-27$3.50/sh+1,397,684$4,891,894→ 8,341,338 total(indirect: See Footnotes) - Sale
Common Stock
2025-06-27$4.16/sh−1,176,332$4,891,894→ 7,165,006 total(indirect: See Footnotes)
Footnotes (3)
- [F1]On June 27, 2025, OrbiMed Private Investments V, LP ("OPI V") exercised common warrants ("Warrants") to purchase 1,397,684 shares of the Issuer's Common Stock for $3.50 per share. OPI V paid the exercise price on a cashless basis, resulting in the Issuer withholding 1,176,332 of the Warrant shares to pay the exercise price and issuing to OPI V the remaining 221,352 shares.
- [F2]These securities are held of record by OPI V. OrbiMed Capital GP V LLC ("GP V") is the general partner of OPI V, and OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI V. The Reporting Person is a member of Advisors.
- [F3]Each of the Reporting Person, OrbiMed Advisors, and GP V disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the "Exchange Act"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.
Documents
Issuer
Corvus Pharmaceuticals, Inc.
CIK 0001626971
Entity typeother
Related Parties
1- filerCIK 0001357522
Filing Metadata
- Form type
- 4
- Filed
- Jun 30, 8:00 PM ET
- Accepted
- Jul 1, 9:17 PM ET
- Size
- 11.0 KB